Lucio Catalano
Overview
Explore the profile of Lucio Catalano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci M, Cesini L, et al.
Ann Hematol
. 2018 Oct;
98(2):361-367.
PMID: 30353388
Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are...
12.
Ombrato A, Manzi A, Palmieri D, Ferrara K, Catalano L, Savoia M
Clin Chem Lab Med
. 2018 Apr;
56(9):e239-e242.
PMID: 29652663
No abstract available.
13.
Cerchione C, Nappi D, Pareto A, Di Perna M, Zacheo I, Picardi M, et al.
Support Care Cancer
. 2018 Mar;
26(9):3111-3116.
PMID: 29574618
Despite novel agents, multiple myeloma is still an incurable disease, especially for elderly and frail patients, who are difficult to manage for concomitant comorbidities as the therapeutic options are limited...
14.
Cerchione C, Nappi D, Pareto A, Romano A, Martinelli V, Picardi M, et al.
Anticancer Drugs
. 2018 Feb;
29(4):371-372.
PMID: 29420336
Renal impairment (RI) is a relevant complication of patients affected by multiple myeloma (MM); it can be present in up to 30-35% of newly diagnosed MM and is linked to...
15.
Cantone E, Di Lullo A, Marano L, Guadagno E, Mansueto G, Capriglione P, et al.
J Med Case Rep
. 2017 Aug;
11(1):219.
PMID: 28793931
Background: Extramedullary plasmacytoma is a rare neoplasm characterized by monoclonal proliferation of plasma cells outside bone marrow. It accounts for 4% of all non-epithelial sinonasal tumors. According to the literature,...
16.
Cerchione C, Nappi D, Di Perna M, Zacheo I, Migliaccio I, Salvatore D, et al.
Clin Case Rep
. 2017 Apr;
5(4):505-507.
PMID: 28396778
In this report, we would like to highlight the efficacy of bendamustine in a heavily pretreated patient, also refractory to pomalidomide. It is conceivable that different therapy combinations in heavily...
17.
Cerchione C, Cerciello G, Avilia S, Pepa R, Pugliese N, Picardi M, et al.
Blood Transfus
. 2016 Nov;
16(1):32-35.
PMID: 27893351
No abstract available.
18.
Cerchione C, Nappi D, Di Perna M, Zacheo I, Pareto A, Picardi M, et al.
Case Rep Hematol
. 2016 Nov;
2016:6745286.
PMID: 27867671
The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced...
19.
Cerchione C, De Renzo A, Di Perna M, Pepa R, Pugliese N, Catalano L, et al.
Support Care Cancer
. 2016 Nov;
25(3):839-845.
PMID: 27812763
Background: In this prospective study, the impact of granulocyte colony-stimulating factors (G-2 CSF) administered during induction treatment with bendamustine plus rituximab for indolent non- Hodgkin Llymphoma (NHL) was evaluated by...
20.
Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, et al.
Support Care Cancer
. 2016 Oct;
24(12):4835-4837.
PMID: 27726031
No abstract available.